Alexis Tandyk, PharmD, BCOP

Tynosynovial giant cell tumor (TGCT) is a rare, locally aggressive condition that significantly impacts patient quality of life and function, yet many patients wait years for diagnosis and may endure multiple surgeries with higher recurrence rates. In this series, Sasha Watson, PharmD (Sylvester Comprehensive Cancer Center) and Alexis Tandyk, PharmD, BCOP (University of Colorado Health), discuss CSF1R inhibitors, the targeted approach transforming TGCT management. They review the pathophysiology and disease burden context, clinical trial evidence from MOTION and ENLIVEN, strategies for differentiating between CSF1R agents, proactive toxicity management frameworks, and practical steps for building a systematic, pharmacist-led TGCT care model.

Tynosynovial giant cell tumor (TGCT) is a rare, locally aggressive condition that significantly impacts patient quality of life and function, yet many patients wait years for diagnosis and may endure multiple surgeries with higher recurrence rates. In this series, Sasha Watson, PharmD (Sylvester Comprehensive Cancer Center) and Alexis Tandyk, PharmD, BCOP (University of Colorado Health), discuss CSF1R inhibitors, the targeted approach transforming TGCT management. They review the pathophysiology and disease burden context, clinical trial evidence from MOTION and ENLIVEN, strategies for differentiating between CSF1R agents, proactive toxicity management frameworks, and practical steps for building a systematic, pharmacist-led TGCT care model.